Affimed (NASDAQ:AFMD) Earns “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Affimed (NASDAQ:AFMD) in a report released on Friday,Benzinga reports. They currently have a $10.00 target price on the biopharmaceutical company’s stock.

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Affimed in a research report on Monday, September 9th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Affimed has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

Affimed Trading Down 4.7 %

NASDAQ:AFMD opened at $3.48 on Friday. The business’s 50 day moving average is $3.49 and its two-hundred day moving average is $4.51. The company has a quick ratio of 2.71, a current ratio of 2.71 and a debt-to-equity ratio of 0.13. Affimed has a 52 week low of $2.92 and a 52 week high of $8.95.

Affimed (NASDAQ:AFMD) last announced its quarterly earnings data on Thursday, September 5th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.00) by ($0.09). The firm had revenue of $0.17 million for the quarter, compared to the consensus estimate of $1.67 million. Affimed had a negative return on equity of 165.35% and a negative net margin of 7,836.26%. On average, research analysts predict that Affimed will post -4.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Affimed

Hedge funds have recently added to or reduced their stakes in the stock. Choreo LLC acquired a new stake in shares of Affimed in the 2nd quarter worth about $54,000. Intellectus Partners LLC grew its position in Affimed by 12.2% in the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock worth $317,000 after purchasing an additional 10,250 shares during the last quarter. FMR LLC increased its stake in shares of Affimed by 30.0% in the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 4,086 shares during the period. Point72 Asset Management L.P. increased its stake in shares of Affimed by 4.6% in the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after purchasing an additional 15,108 shares during the period. Finally, Jane Street Group LLC bought a new stake in shares of Affimed during the third quarter valued at approximately $44,000. 30.82% of the stock is currently owned by institutional investors.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.